Fresenius signs exclusive development deal with WuXi Biologics to expand biosimilars pipeline
Bitget2026/11/02 06:01- Fresenius entered an exclusive development agreement with WuXi Biologics, securing options for up to 37 biosimilar candidates over the next decade.
- The deal could expand its marketed and pipeline portfolio from 29 to 66 molecules, targeting over €370 billion in originator sales.
- Selected programs will use fee-for-service payments, with Fresenius retaining exclusive global commercialization rights and full product economics.
- Manufacturing strategy remains under its control, including potential transfers of selected products to wholly owned mAbxience.
- Operating cash flow will fund the agreement without new financing; 2026 guidance and the existing 2030 Biopharma ambition remain unchanged.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
